DR. RAHUL ATUL PARIKH, MD, PHD
Osteopathic Medicine in Pittsburgh, PA
License number
Pennsylvania MD445914
Category
Osteopathic Medicine
Type
Hematology & Oncology
License number
Pennsylvania MT189101
Category
Osteopathic Medicine
Type
Internal Medicine
Address
Address
5150 Floor Upmc Cancer Pavilion, Pittsburgh, PA 15232
Phone
(412) 864-7955
Personal information
See more information about RAHUL ATUL PARIKH at radaris.comName
Address
Phone
5405 Guarino Rd, Pittsburgh, PA 15217
Professional information
Dr. Rahul A Parikh, Pittsburgh PA - MD (Doctor of Medicine)
Specialties:
Hematology, Hematology & Oncology
Address:
UPMC CANCER PAVILLON
5150 Centre Ave SUITE 5TH, Pittsburgh 15232
(412) 623-6723 (Phone), (814) 838-0443 (Fax)
5150 Centre Ave SUITE 5TH, Pittsburgh 15232
(412) 623-6723 (Phone), (814) 838-0443 (Fax)
Languages:
English
Hospitals:
UPMC CANCER PAVILLON
5150 Centre Ave SUITE 5TH, Pittsburgh 15232
Upmc Shadyside
5230 Center Ave, Pittsburgh 15232
5150 Centre Ave SUITE 5TH, Pittsburgh 15232
Upmc Shadyside
5230 Center Ave, Pittsburgh 15232
Rahul Atul Parikh, Pittsburgh PA
Specialties:
Internist
Address:
5150 Centre Ave, Pittsburgh, PA 15232
5230 Centre Ave, Pittsburgh, PA 15232
5230 Centre Ave, Pittsburgh, PA 15232
Genetic Changes In Atm And Atr/Chek1 As Prognostic Indicators In Cancer
US Patent:
8466123, Jun 18, 2013
Filed:
Feb 28, 2012
Appl. No.:
13/407165
Inventors:
Susanne M. Gollin - Pittsburgh PA, US
Rahul Atul Parikh - Pittsburgh PA, US
Xin Huang - Wexford PA, US
Rahul Atul Parikh - Pittsburgh PA, US
Xin Huang - Wexford PA, US
Assignee:
Univeristy of Pittsburgh—of The Commonwealth System of Higher Education - Pittsburgh PA
International Classification:
A61K 48/00, C12Q 1/68
US Classification:
514 44, 435 6, 435325, 435375
Abstract:
The present invention relates to the discovery that, in human cancer, an 11q deletion of ATM together with an increase in ATR and CHEK1 expression correlates with resistance to ionizing radiation which could be overcome by inhibition of the ATR/CHEK1 pathway. It provides for methods of identifying patients unlikely to exhibit an adequate response to radiation therapy and/or chemotherapy who may benefit from ATR/CHEK1 pathway inhibition, as well as methods of treating said patients.
Genetic Changes In Atm And Atr/Chek1 As Prognostic Indicators In Cancer
US Patent:
2010017, Jul 8, 2010
Filed:
Sep 15, 2009
Appl. No.:
12/586052
Inventors:
Susanne M. Gollin - Pittsburgh PA, US
Rahul Atul Parikh - Pittsburgh PA, US
Xin Huang - Wexford PA, US
Rahul Atul Parikh - Pittsburgh PA, US
Xin Huang - Wexford PA, US
International Classification:
A61K 31/7088, C12Q 1/68, C12Q 1/02
US Classification:
514 44 A, 435 6, 514 44 R, 435 29
Abstract:
The present invention relates to the discovery that, in human cancer, an 11deletion of ATM together with an increase in ATR and CHEK1 expression correlates with resistance to ionizing radiation which could be overcome by inhibition of the ATR/CHEK1 pathway. It provides for methods of identifying patients unlikely to exhibit an adequate response to radiation therapy and/or chemotherapy who may benefit from ATR/CHEK1 pathway inhibition, as well as methods of treating said patients.
Genetic Changes In Atm And Atr/Chek1 As Prognostic Indicators In Cancer
US Patent:
2012029, Nov 22, 2012
Filed:
May 24, 2012
Appl. No.:
13/480358
Inventors:
Susanne M. Gollin - Pittsburgh PA, US
Rahul Atul Parikh - Pittsburgh PA, US
Xin Huang - Menlo Park CA, US
Rahul Atul Parikh - Pittsburgh PA, US
Xin Huang - Menlo Park CA, US
International Classification:
C12Q 1/68, G01N 21/64, A61K 31/713, A61P 35/00, A61K 31/4709, A61K 31/4965, A61K 31/497, C12Q 1/06, A61K 31/7105
US Classification:
514 44 A, 435 611, 435 39, 514 44 R, 514305, 51425506, 51425505
Abstract:
The present invention relates to the discovery that, in human cancer, an 11q deletion of ATM together with an increase in ATR and CHEK1 expression correlates with resistance to ionizing radiation which could be overcome by inhibition of the ATR/CHEK1 pathway. It provides for methods of identifying patients unlikely to exhibit an adequate response to radiation therapy and/or chemotherapy who may benefit from ATR/CHEK1 pathway inhibition, as well as methods of treating said patients.
Genetic Changes In Atm And Atr/Chek1 As Prognostic Indicators In Cancer
US Patent:
2013033, Dec 19, 2013
Filed:
Jun 10, 2013
Appl. No.:
13/914321
Inventors:
Rahul Atul Parikh - Pittsburgh PA, US
Xin Huang - Menlo Park CA, US
Xin Huang - Menlo Park CA, US
Assignee:
UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION - Pittsburgh PA
International Classification:
C12Q 1/68
US Classification:
514 44 A, 435 611, 435 39, 514 44 R, 536 2431, 514305
Abstract:
The present invention relates to the discovery that, in human cancer, an 11q deletion of ATM together with an increase in ATR and CHEK1 expression correlates with resistance to ionizing radiation which could be overcome by inhibition of the ATR/CHEK1 pathway. It provides for methods of identifying patients unlikely to exhibit an adequate response to radiation therapy and/or chemotherapy who may benefit from ATR/CHEK1 pathway inhibition, as well as methods of treating said patients.
Genetic Changes In Atm And Atr/Chek1 As Prognostic Indicators In Cancer
US Patent:
8263329, Sep 11, 2012
Filed:
Mar 28, 2008
Appl. No.:
12/079900
Inventors:
Susanne M. Gollin - Pittsburgh PA, US
Rahul Atul Parikh - Pittsburgh PA, US
Xin Huang - Menlo Park CA, US
Rahul Atul Parikh - Pittsburgh PA, US
Xin Huang - Menlo Park CA, US
Assignee:
University of Pittsburgh - Of The Commonwealth System Of Higher Education - Pittsburgh PA
International Classification:
C12Q 1/68
US Classification:
435 6, 435325, 435375
Abstract:
The present invention relates to the discovery that, in human cancer, an 11q deletion of ATM together with an increase in ATR and CHEK1 expression correlates with resistance to ionizing radiation which could be overcome by inhibition of the ATR/CHEK1 pathway. It provides for methods of identifying patients unlikely to exhibit an adequate response to radiation therapy and/or chemotherapy who may benefit from ATR/CHEK1 pathway inhibition, as well as methods of treating said patients.